Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benzocaine→

Benzocaine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
94-09-7
Molecular formula
C9H11NO2
Molecular weight
165.19 g/mol
Drug class
Ester-type local anaesthetic
Mechanism of action
Reversibly blocks voltage-gated sodium channels in neuronal membranes, preventing initiation and propagation of nerve impulses and producing local loss of sensation.
Indications / reported uses
  • Topical oromucosal anaesthesia and temporary relief of pain from minor mouth and throat irritation in authorised products
  • Topical local anaesthesia for minor skin or mucosal procedures in product-specific formulations; avoid use in infants and observe methemoglobinaemia warnings

Sources: US FDA — Benzocaine and methemoglobinaemia safety communication · NLM MedlinePlus — Benzocaine topical · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benzocaine Environmental Risk Assessment (ERA) (the Benzocaine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.